Welcome to our dedicated page for PHARMA MAR SA NEW news (Ticker: PHMMF), a resource for investors and traders seeking the latest updates and insights on PHARMA MAR SA NEW stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PHARMA MAR SA NEW's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PHARMA MAR SA NEW's position in the market.
PharmaMar (MSE: PHM) announced the publication of a study in the Life Science Alliance journal on plitidepsin's efficacy against COVID-19. The research indicates that plitidepsin exhibits potent antiviral activity against SARS-CoV-2 variants, including Omicron, at low concentrations. In vivo studies showed a 99% reduction in viral loads in treated animals. The Phase I-II APLICOV-PC trial, involving 45 patients, confirmed safety and clinical efficacy, with 74% of moderate disease patients discharged within a week. These findings support the ongoing Phase III NEPTUNO trial in 17 hospitals across Europe and Latin America.
FAQ
What is the market cap of PHARMA MAR SA NEW (PHMMF)?
